Abstract

Members of the Herpesviridae, including the medically important alphaherpesvirus varicella-zoster virus (VZV), induce fusion of the virion envelope with cell membranes during entry, and between cells to form polykaryocytes in infected tissues. The conserved glycoproteins, gB, gH and gL, are the core functional proteins of the herpesvirus fusion complex. gB serves as the primary fusogen via its fusion loops, but functions for the remaining gB domains remain unexplained. As a pathway for biological discovery of domain function, our approach used structure-based analysis of the viral fusogen together with a neutralizing antibody. We report here a 2.8 Å cryogenic-electron microscopy structure of native gB recovered from VZV-infected cells, in complex with a human monoclonal antibody, 93k. This high-resolution structure guided targeted mutagenesis at the gB-93k interface, providing compelling evidence that a domain spatially distant from the gB fusion loops is critical for herpesvirus fusion, revealing a potential new target for antiviral therapies.

Herpesvirus virions have an outer lipid membrane dotted with glycoproteins that enable fusion with cell membranes to initiate entry and establish infection. Here the authors elucidate the structural mechanism of a neutralizing antibody derived from a patient infected by the herpesvirus varicella-zoster virus and targeted to its fusogen, glycoprotein-B.

Details

Title
A glycoprotein B-neutralizing antibody structure at 2.8 Å uncovers a critical domain for herpesvirus fusion initiation
Author
Oliver, Stefan L 1   VIAFID ORCID Logo  ; Xing, Yi 2 ; Dong-Hua, Chen 3   VIAFID ORCID Logo  ; Roh, Soung Hun 4 ; Pintilie, Grigore D 5 ; Bushnell, David A 3   VIAFID ORCID Logo  ; Sommer, Marvin H 1 ; Yang, Edward 1 ; Carfi, Andrea 6 ; Chiu Wah 7   VIAFID ORCID Logo  ; Arvin, Ann M 8   VIAFID ORCID Logo 

 Stanford University School of Medicine, Department of Pediatrics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 GSK Vaccines, Cambridge, USA (GRID:grid.168010.e); Syros Pharmaceuticals, Inc. Cambridge, USA (GRID:grid.168010.e) 
 Structural Biology, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 Institute of Molecular Biology & Genetics, Seoul National University, Department of Biological Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905) 
 Bioengineering, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 GSK Vaccines, Cambridge, USA (GRID:grid.168010.e); Moderna, Cambridge, USA (GRID:grid.479574.c) (ISNI:0000 0004 1791 3172) 
 Bioengineering, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Microbiology and Immunology, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Division of Cryo-EM and Bioimaging SSRL, SLAC National Accelerator Laboratory, Menlo Park, USA (GRID:grid.445003.6) (ISNI:0000 0001 0725 7771) 
 Stanford University School of Medicine, Department of Pediatrics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Microbiology and Immunology, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2435011322
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.